Recent Updates
Recently added Catalysts

FS VH S/D 4 s-apr

Phase 3

Face-lift | Monoclonal antibody | Other |Baxter International Inc.|Last Updated: Oct 8, 2012

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedNO_TREATMENT_CONTROLLED
Total Trials1
Total Enrollment75
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00999141Efficacy and Safety of FS VH S/D 4 S-apr for Flap Adherence in RhytidectomyPHASE3 COMPLETED 75Sep 1, 2009Feb 1, 2010Oct 8, 20126 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Total Volume of Drainage on Each Side of the Face
24 hours (± 4h) after surgery

Total drainage volume collected from each side of the face. One side of face is treated with FS VH S/D 4 s-apr (FS); the other side is treated using standard of care (SoC).

Number of AEs Related to the Investigational Product (FS VH S/D 4 S-apr)
Day 0 (day of surgery) through postoperative Day 14
Secondary Endpoints
Participants' First Occurrence of Hematoma or Seroma by Study Day
Day 0 (day of surgery) through postoperative day 14
Participants With Hematoma/Seroma by Study Day
Day 0 (day of surgery) through postoperative day 14
Number of Participants With Hematoma/Seroma Anytime During the Study
Day 0 (day of surgery) through postoperative Day 14
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingSINGLE
ModelSINGLE_GROUP
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
FS VH S/D 4 s-aprEXPERIMENTALOne side of face will be treated with the investigational product (FS VH S/D 4 s-apr) as an adjuvant to the standard of care. Please note: Each subject will participate in both arms (investigational product and standard of care) simultaneously, and will serve as his/her own control.
Standard of Care (SoC)NO_INTERVENTIONOther side of face will receive standard of care. Please note: Each subject will participate in both arms (investigational product and standard of care) simultaneously, and will serve as his/her own control.
Interventions
NameTypeDescription
FS VH S/D 4 s-aprBIOLOGICALFS VH S/D 4 s-apr will be applied (using spray device provided by Sponsor) to the subcutaneous plane (intraoperative, topical administration) in both the neck and the face area.
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 75 Years
SexALL
Healthy VolunteersYes
Study Sites6

Inclusion Criteria: * Male or female subject is 18 to 75 years of age at the time of screening * Subject is planned for facial rhytidectomy * Subject has read, understood and signed the written informed consent * Subject is healthy, as determined by the investigator using standard pre-operative ass...

Countries:United States
Unlock Eligibility Criteria